Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bretten – page 80

1 040 clinical trials in Bretten, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bretten at a glance
1 040
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 040 trials in Bretten

Open in trial search

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Study on the Safety and Effectiveness of MK-5475 for Adults with Pulmonary Hypertension and COPD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frespaciguat
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of DKN-01 with Drug Combination for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Leap Therapeutics Inc.

Burkitt's lymphoma+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Hairy cell leukaemia

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mesna
  • Sponsor:Kite Pharma Inc.

Richter's syndrome

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Kite Pharma Inc.

Study of Venetoclax and Azacitidine for Adults 18+ with Acute Myeloid Leukemia Not Eligible for Standard Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:University of Leipzig

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of HRO350 for Patients with Mild-to-Moderate Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pehero
  • Sponsor:Arctic Bioscience AS

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bretten

What the registry says about research in the country

01 Infectious Disease Prevention

Ongoing clinical trials focusing on meningococcal infection prevention through vaccination studies. Research is evaluating the long-term effectiveness of a quadrivalent conjugate vaccine in providing protection against multiple bacterial strains.

  • Vaccine Immunogenicity
  • Long-term Protection
  • Pediatric Vaccination

Studies involve children and adolescents across multiple European centers, examining immune responses and safety profiles of booster vaccinations administered at 5- and 10-year intervals.

02 Pediatric Immunology

Research centered on understanding the persistence of immunity in young populations. The booster vaccination studies are specifically designed to evaluate immune system responses in previously vaccinated children.

  • Immune Response Duration
  • Booster Effectiveness
  • Safety Assessment

These trials are being conducted across multiple sites in Finland, Germany, Spain, and Hungary, focusing on protective immunity development in pediatric populations.

03 Preventive Medicine

Investigation of preventive strategies against multiple meningococcal serogroups through advanced vaccine technology. The research aims to establish optimal timing for booster doses.

  • Multi-strain Protection
  • Vaccination Schedule Optimization
  • Population Health Impact

The study evaluates the effectiveness of vaccination strategies in providing comprehensive protection against various meningococcal strains.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.